Outlook 2024
Annual Industry Ranking And Forecast
VIEW NOWGenerics Bulletin is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.
Teva is ramping up its activities in US biosimilars, with the launch of its Alvotech-partnered Humira rival imminent and a Stelara biosimilar slated for launch in February 2025. Tom Rainey, the firm’s senior vice president of US market access, talks about the opportunities on the horizon and how the firm is balancing its partnership model with in-house development.
In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.
Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.
Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.
Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Speaking at Medicines for Europe’s 20th annual biosimilar medicines conference, Isabell Remus, chair of Medicines for Europe’s biosimilar medicines sector group, looks to the future for European biosimilars over the next decade and outlines the potential that can be realized – but only if a comprehensive strategy for biosimilars is put in place.
The European Parliament has voted for a deal agreed with the council of minister to ensure polluters pay for cleaning up urban wastewater.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.
Four years after entering a guilty plea in response to US generic price-fixing allegations, the former Sandoz US vice-president of business contracting and analytics, Hector Armando Kellum, will serve his sentence outside of a jail cell and pay a token criminal fine.
As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.
Four years after entering a guilty plea in response to US generic price-fixing allegations, the former Sandoz US vice-president of business contracting and analytics, Hector Armando Kellum, will serve his sentence outside of a jail cell and pay a token criminal fine.
As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.
Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.
The US Court of Appeals for the Second Circuit has backed up a US district court decision to dismiss purchaser and payer claims linked to so-called “pay-for-delay” agreements with generics firms over nebivolol rivals to Bystolic.
Biocon Limited has struck a “semi-exclusive” distribution and supply deal with Mexican player Medix for local rights to the Indian firm’s liraglutide generic rival to Saxenda.
Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.
While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.
Waverley Pharma has blamed deep discounting and heavy competition for its decision to step back from generics and focus entirely on novel drug development.
Amneal has joined the ranks of generics manufacturers who had to pay millions to settle legal claims linked to the sector’s alleged role in the US opioid epidemic.
Teva is putting its Japanese generics business up for sale, in an exit from the country’s generics market that has led the Israeli firm to register a substantial impairment charge in Q1.
Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.
Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.
With an already established network, Formycon’s aflibercept biosimilar licensee Klinge follows in the same footsteps by picking MS Pharma as its MENA region partner.
As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.
Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.
Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.
Amneal has joined the ranks of generics manufacturers who had to pay millions to settle legal claims linked to the sector’s alleged role in the US opioid epidemic.
Generics Bulletin previews the most noteworthy and anticipated events for May 2024.
Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.
Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.
With an already established network, Formycon’s aflibercept biosimilar licensee Klinge follows in the same footsteps by picking MS Pharma as its MENA region partner.
Four years after entering a guilty plea in response to US generic price-fixing allegations, the former Sandoz US vice-president of business contracting and analytics, Hector Armando Kellum, will serve his sentence outside of a jail cell and pay a token criminal fine.
Dr Reddy’s shapes journey to the top 5 league on home turf, backed by a string of deals with big pharma to bridge portfolio gaps and supplement its base business. Can they deliver impactful gains in the competitive Indian market?
As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.
Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.
Boehringer Ingelheim has revealed that it will supply its 50mg/ml adalimumab biosimilar to Quallent Pharmaceuticals in the US, under a recently-announced initiative that also involves Teva and Alvotech’s 100mg/ml Humira rival.
In what has been described by some analysts as a “solid start” to 2024, Organon has reported a 46% increase in revenue from its biosimilars portfolio amid broader improvement.
Teva is ramping up its activities in US biosimilars, with the launch of its Alvotech-partnered Humira rival imminent and a Stelara biosimilar slated for launch in February 2025. Tom Rainey, the firm’s senior vice president of US market access, talks about the opportunities on the horizon and how the firm is balancing its partnership model with in-house development.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.